1. Home
  2. AVDL vs APOG Comparison

AVDL vs APOG Comparison

Compare AVDL & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • APOG
  • Stock Information
  • Founded
  • AVDL 2015
  • APOG 1949
  • Country
  • AVDL Ireland
  • APOG United States
  • Employees
  • AVDL N/A
  • APOG N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • APOG Auto Parts:O.E.M.
  • Sector
  • AVDL Health Care
  • APOG Consumer Discretionary
  • Exchange
  • AVDL Nasdaq
  • APOG Nasdaq
  • Market Cap
  • AVDL 861.4M
  • APOG 818.5M
  • IPO Year
  • AVDL 1996
  • APOG N/A
  • Fundamental
  • Price
  • AVDL $10.83
  • APOG $41.97
  • Analyst Decision
  • AVDL Strong Buy
  • APOG Hold
  • Analyst Count
  • AVDL 7
  • APOG 1
  • Target Price
  • AVDL $18.71
  • APOG $45.00
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • APOG 397.9K
  • Earning Date
  • AVDL 08-07-2025
  • APOG 06-27-2025
  • Dividend Yield
  • AVDL N/A
  • APOG 2.48%
  • EPS Growth
  • AVDL N/A
  • APOG N/A
  • EPS
  • AVDL N/A
  • APOG 2.36
  • Revenue
  • AVDL $194,450,000.00
  • APOG $1,376,100,000.00
  • Revenue This Year
  • AVDL $56.86
  • APOG $6.76
  • Revenue Next Year
  • AVDL $30.45
  • APOG N/A
  • P/E Ratio
  • AVDL N/A
  • APOG $17.72
  • Revenue Growth
  • AVDL 252.64
  • APOG N/A
  • 52 Week Low
  • AVDL $6.38
  • APOG $37.53
  • 52 Week High
  • AVDL $17.30
  • APOG $87.93
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 72.02
  • APOG 52.42
  • Support Level
  • AVDL $8.74
  • APOG $40.92
  • Resistance Level
  • AVDL $9.56
  • APOG $42.70
  • Average True Range (ATR)
  • AVDL 0.41
  • APOG 1.57
  • MACD
  • AVDL 0.18
  • APOG -0.08
  • Stochastic Oscillator
  • AVDL 89.88
  • APOG 54.90

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.

Share on Social Networks: